Shuren touts openFDA; Surgical hemostatic device performs well on animals;

@FierceMedDev: ICYMI: approves more innovative med tech, faster in first half. Story | Follow @FierceMedDev

@VarunSaxena2: Covidien acquisition of Reverse Medical illustrates vascular device focus. Article | Follow @VarunSaxena2

@EmilyWFierce: $MDT shareholders rail against company's pending merger with $COV. Story via Pioneer Press | Follow @EmilyWFierce

> Jeffrey Shuren, head of the FDA's device arm, said its newly created application programming interface enabling sharing of medical device data "can be a powerful tool for generating hypotheses for further investigation or inquiry and can inform the development of safer, more effective technologies." The API is part of the openFDA project initiative to allow easier access to reports dating back to the 1990s. Story

> Arch Therapeutics ($ARTH) announced hopeful results of a preclinical study of its AC5 Surgical Hemostatic device in animals receiving a blood thinner. Release

> A team of electrical engineers at Stanford University developed a method to power medical devices through magnetic fields below the skin. More

Biotech News

@FierceBiotech: Roche extends biotech shopping spree with $8.3B InterMune buyout. News | Follow @FierceBiotech

@JohnCFierce: Getting the feeling today that the slower summer news cycle is coming to a close. | Follow @JohnCFierce

@EmilyMFierce: ICYMI: UCSF spinout launches crowdfunding campaign for Ebola drug. Story | Follow @EmilyMFierce

> Allergic reactions force Regado to pull the plug on PhIII anticoagulant study. Story

> J&J snaps up Covagen and its protein-antibody fusion platform. News

> Merck and Advaxis forge another no-money-down IO development pact. Article

Pharma News

@FiercePharma: Top-read over the weekend: Pfizer eyes Actavis in backup plan to another AstraZeneca bid. More | Follow @FiercePharma

@TracyStaton: Novo Nordisk CEO on the house that Victoza built and the future of diabetes R&D. Article via FierceBiotech | Follow @TracyStaton

@EricPFierce: As EvaluatePharma figures, 2014 could rival 2009 in M&A action, and that is a lot. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Valeant, Ackman pass threshold to call pivotal Allergan meeting. Story | Follow @CarlyHFierce

> Roche ready to roll on InterMune's lung drug with $8.6B buyout deal. Story

> Glaxo's ViiV venture adds $5B combo pill to its HIV-fighting armory. Article

> Jumping into global M&A mix key to India growing its pharma industry. More

CRO News

> Quintiles and Illumina look to jump-start cancer R&D with genomics sweepstakes. Article

> Evotec teams up with malaria nonprofit in open R&D project. Report

> Parexel: Biotech's boom pays dividends for CROs. More

> CRO PharPoint signs up to get Otologic's hearing drug into the clinic. Story

> Clinverse reels in a $9.1M funding round to expand its trial tech. Article

Biotech IT News

> Illumina teams with AstraZeneca, J&J and Sanofi on cancer diagnostic. More

> Rollout of openFDA continues with drug labeling, medtech adverse event APIs. Article

> Clinverse and Comprehend raise $30M in separate financing rounds. More

> uBiome raises $4.5M as first batch of Y Combinator biotechs pitch to investors. Story

> Rock Health backs cloud-based R&D platform as Abbott comes on board. Article

Animal Health News

> Merck releases tilapia vaccine. News

> China's Skystar Bio-Pharmaceutical sees revenue grow 25%. Report

> FDA warns Kentucky drug compounder after sick, dead horses reported. Article

> Boehringer Ingelheim's Vetmedica to open $30M facility near Kansas City. Story

> Kinavet CA-1 moves forward to trials. Item

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.